selective estrogen receptor modulator

(redirected from Selective estrogen receptor modulators)
Also found in: Dictionary.
Related to Selective estrogen receptor modulators: raloxifene, Aromatase inhibitors

modulator

 [mod´u-la″ter]
a specific inductor or agent that brings out characteristics peculiar to a definite region.
selective estrogen receptor modulator (SERM) an agent that activates some estrogen receptors but not others, thereby having estrogenlike effects on target tissues (such as bone) without affecting other tissues that have estrogen receptors.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

selective estrogen receptor modulator (SERM),

pharmaceutical agent with selective estrogen receptor affinity; current preparations have a primary effect on bone and cardiovascular tissues and less effect on endometrial, genital, and breast tissues.
Farlex Partner Medical Dictionary © Farlex 2012

selective estrogen receptor modulator

n.
Abbr. SERM Any of a group of nonsteroidal drugs, such as raloxifene and tamoxifen, that bind to estrogen receptors and act in some cases as estrogen agonists and in others as estrogen antagonists.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

selective estrogen receptor modulator

Designer estrogen, SERM Therapeutics A drug–eg, idoxifene, raloxifene–Evista®, which, like estrogen, prevents bone loss and ↓ cholesterol but, unlike estrogen, does not stimulate the endometrium and breast and thus does not ↑ risk of breast and endometrial CA. See Estrogen receptor, Raloxifene.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

se·lec·tive es·tro·gen re·cep·tor mod·u·la·tor

(SERM) (sĕ-lek'tiv es'trŏ-jen rĕ-sep'tŏr mod'yū-lā'tŏr)
Pharmaceutical agent with selective estrogen receptor affinity; current preparations have a primary effect on bone and cardiovascular tissues and less effect on endometrial, genital, and breast tissues.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

Selective estrogen receptor modulator

A hormonal preparation that offers the beneficial effects of hormone replacement therapy without the increased risk of breast and uterine cancer associated with HRT.
Mentioned in: Osteoporosis
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
Selective estrogen receptor modulator drugs (SERM) are well known as designer estrogens as it has high affinity toward the receptor and is selective in nature.
Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
Pharmacokinetics of selective estrogen receptor modulators. Clin pharmacokinet.
Shah, "Selective estrogen receptor modulators: tissue specificity and clinical utility," Clinical Interventions in Aging, vol.
Selective estrogen receptor modulators (SERMs) and selective androgen receptor modulators (SARMs) are two classes of drugs under development for a variety of diseases due to their high specificity for ER or AR, selective anabolic activity, lack of virilizing side effect, and ability to extend estrogen or androgen therapy [51].
rosea is low in side effects compared to synthetic selective estrogen receptor modulators (SERMS).
Tamoxifen belongs to selective estrogen receptor modulators (SERMs) class of drugs, which is having both estrogenic and anti-estrogenic effects.
Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Use of the next most popular form of osteoporosis medication, the selective estrogen receptor modulators, declined from 4.2% of all older women in 2002-2003 to 1.6% in 2010-2011, according to the AHRQ.
24, 2014, 1 year after the USPSTF first issued a "B" rating also, for use of the selective estrogen receptor modulators, tamoxifen, or raloxifene (Evista) for women at high risk for breast cancer and low risk for side effects.
Raloxifene is to be from SERM drug groups (selective estrogen receptor modulators).

Full browser ?